CoChat

Vascular Targets for the Treatment of Portal Hypertension

The DOI matches its Crossref record; 257 of the 257 references it cites were found in a registry or an index.

Abstract

Portal hypertension is the main driver for severe complications in patients with liver cirrhosis. With improved understanding of molecular pathways that promote hepatic vascular remodeling, vasoconstriction, and sinusoidal capillarization potential vascular targets for the treatment of portal hypertension have been identified. Inhibition of vascular endothelial and platelet-derived growth factors–driven angiogenesis has been shown to reduce portal pressure and decrease hepatic inflammation. Angiopoietin/Tie signaling represents additional promising vascular targets in liver disease. The eNOS-NO-sGC-cGMP pathway modulates sinusoidal vasoconstriction and capillarization. Nuclear farnesoid X receptor (FXR) agonists decrease intrahepatic vascular resistance by inhibition of fibrogenesis and sinusoidal remodeling. Statins ameliorate endothelial dysfunction, decrease portal pressure, and reduce fibrogenesis. Anticoagulation with low-molecular heparin or anti-Xa inhibitors improved portal hypertension by deactivation of hepatic stellate cells and potentially via reduction of sinusoidal microthrombosis. This review summarizes important vascular targets for treatment of portal hypertension that have shown promising results in experimental studies.

Overview

Integrity signals

Registry

Crossref · 10.1055/s-0039-1693115

Cites

257 of 257 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 257 references

Cited by

See all 28

Metadata

Authors
Brusilovskaya, K., Königshofer, P., Schwabl, P., & Reiberger, T.
Affiliations
Medical University of Vienna (AT)
Corresponding author
Reiberger, Thomas
Venue
Seminars in Liver Disease
Published
2019-07-17
Volume
39
Issue
04
Pages
483-501
ISSN
  • 0272-8087 (ISSN-L)
  • 1098-8971
OpenAlex
W2956285561
Cited by
28
References
257
Citations by year
2026: 2 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 8 · 2020: 3
FWCI
2.57
Type
journal article
Language
en
Open access
closed
Locations
  • Seminars in Liver Disease (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Keywords
portal hypertension, liver cirrhosis, angiogenesis, vascular endothelial growth factor, platelet-derived growth factor, nitric oxide signaling, endothelial nitric oxide synthase, statins, endothelial dysfunction, liver fibrosis, low molecular weight heparin, anti-Xa inhibitors, hepatic stellate cells, sinusoidal capillarization, vasoconstriction
MeSH terms
Soluble Guanylyl Cyclase, Receptor, Farnesoid X-Activated, Anticoagulants, Cyclic GMP, Humans, Hypertension, Portal, Neovascularization, Pathologic, Nitric Oxide, Receptors, Cytoplasmic and Nuclear, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vascular Targets for the Treatment of Portal Hypertension. https://app.cochat.ai/papers/10.1055/s-0039-1693115
The paper
Brusilovskaya, K., Königshofer, P., Schwabl, P., & Reiberger, T. (2019). Vascular Targets for the Treatment of Portal Hypertension. Seminars in Liver Disease. https://doi.org/10.1055/s-0039-1693115

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.